CMC/IND Enabling Studies
SBS-1000 Phase 1
SBS-147 CMC and IND-enabling Studies
Acute and Chronic Pain
Arylepoxamides are first in class compounds which bind to the newly discovered receptor, the AEAr. In preclinical studies, arylepoxamides demonstrate potent analgesia for acute and chronic pain and a clean safety profile lacking respiratory depression, physical dependence, and reward behavior.
SBS-226 Lead Optimization
Opioid Use Disorder
Our MOR Agonist/DOR Antagonists are synthetic compounds that are structurally similar to mitragynine pseudoindoxyl - one of the primary alkaloids in Kratom. SBS-226 is a new chemical entity (NCE) synthesized and developed in the Majumdar Lab. SBS-226 is a very weak MOR agonist and potent DOR antagonist. Preclinically, SBS-226 can ameliorate opioid withdrawal but does not demonstrate abuse potential, respiratory depression, or physical dependence.
Irreversible MOR Antagonists
SBS-371 Lead Optimization
SBS-371 is a first in class irreversible MOR antagonist being developed for the acute treatment and prophylaxis of opioid overdose. The opioid epidemic has transformed to a fentanyl epidemic and urgently demands more potent, longer lasting MOR antagonists. Preclinically, SBS-371 can prevent and reverse a synthetic opioid overdose (e.g. fentanyl and fentanyl derivatives).
Sigma Antagonist / DAT Inhibitor
SBS-518 Lead Optimization
Stimulant Use Disorder (Cocaine and Methamphetamine)
Our dual acting sigma antagonist / dopamine active transporter (DAT) inhibitor is a first in class compound to treat stimulant use disorder (StUD). There are ~3.2 M people with StUD and ~57 K StUD overdose related deaths per year. Preclinically, SBS-518 reduces cocaine self-administration and reduces cocaine-induced extracellular dopamine increases.